Back to top
more

BioRad Laboratories (BIO)

(Real Time Quote from BATS)

$262.78 USD

262.78
110,279

-9.40 (-3.45%)

Updated Aug 6, 2025 12:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.

Zacks Equity Research

Allscripts (MDRX) Up 4.5% Since Q4 Earnings: What's Driving It?

by Zacks Equity Research

Allscripts' (MDRX) stock rallies on better-than-expected fourth-quarter performance and recent alliances.

Zacks Equity Research

Bio-Rad's (BIO) Product Launches Aid Growth, Global Arm Strong

by Zacks Equity Research

Bio-Rad's (BIO) Diagnostics business registers growth across all its product lines, driven by the recovery of routine testing.

Zacks Equity Research

Chemed (CHE) Roto-Rooter Sales Robust Despite COVID-19 Woes

by Zacks Equity Research

Chemed's (CHE) Roto-Rooter business gains from growing demand for plumbing, drain cleaning and excavation and water restoration services.

Zacks Equity Research

Here's Why You Should Invest in Bio-Rad (BIO) Stock Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO) on solid recovery in most of its key global markets as well as an uptick in demand for COVID-related products.

Zacks Equity Research

Cooper Companies (COO) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Cooper Companies' (COO) fiscal first-quarter earnings reflect solid segmental performance.

Zacks Equity Research

Thermo Fisher (TMO) Extends Collaboration With Symphogen

by Zacks Equity Research

Thermo Fisher's (TMO) recent extension of collaboration with Symphogen is intended to support biopharmaceutical discovery and development.

Zacks Equity Research

Medtronic (MDT) Gains Market Share Despite COVID Headwinds

by Zacks Equity Research

In Respiratory Interventions, despite the year-over-year headwind, as ventilator sales continue to return to pre-pandemic levels, Medtronic (MDT) gains about 400 basis points of share.

Zacks Equity Research

Quidel (QDEL) Rallies 17.4% Since Posting Q4 Earnings Beat

by Zacks Equity Research

Quidel (QDEL) stock rallies on better-than-expected fourth-quarter performance and strong diagnostics portfolio.

Zacks Equity Research

Patterson Companies (PDCO) Q3 Earnings Beat, Revenues Lag

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal third-quarter 2022 results benefit from strength in the Dental and Animal Health segments.

Zacks Equity Research

Insulet (PODD) Product Volume Up, COVID-Led Softness Persists

by Zacks Equity Research

Insulet's (PODD) drug delivery revenues surge led by increased production volumes, driven by higher-than-expected demand from its partner.

Zacks Equity Research

Henry Schein (HSIC) Expands Data Analytics to Private Practices

by Zacks Equity Research

Henry Schein's (HSIC) introduction of Jarvis Analytics for Private Practices offers practice owners a simple, powerful tool to help improve practice success through data-driven decisions.

Zacks Equity Research

Cooper Companies (COO) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Cooper Companies' (COO) fiscal first-quarter results are likely to reflect segmental strength.

Zacks Equity Research

What's in Store for Patterson Companies' (PDCO) Q3 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal third-quarter results are likely to reflect improvement at Animal Health segment.

Zacks Equity Research

SmileDirectClub (SDC) Q4 Earnings Lag Estimates, Margin Falls

by Zacks Equity Research

SmileDirectClub (SDC) reports lower-than-expected results for the fourth quarter, issues full-year 2022 sales guidance.

Zacks Equity Research

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS) on continued growth in its consumer-centric digital solutions.

Zacks Equity Research

National Vision (EYE) Q4 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Strength in America's Best and Eyeglass World brands drove National Vision's (EYE) performance in the fourth quarter of 2021.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Q4 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Despite a year-over-year decline in both earnings and revenues, DENTSPLY SIRONA's (XRAY) fourth-quarter results benefit from Technologies & Equipment business.

Zacks Equity Research

Inari Medical (NARI) Gains 12.5% Despite In-Line Q4 Earnings

by Zacks Equity Research

Inari Medical's (NARI) fourth-quarter results benefit from significant progress made across all of its growth drivers.

Zacks Equity Research

Here's Why You Should Invest In Henry Schein (HSIC) Now

by Zacks Equity Research

Investors are optimistic about Henry Schein's (HSIC) favorable dental business trends and bullish fourth-quarter 2021 performance.

Urmimala Biswas headshot

3 Medical Device Stocks Poised to Beat This Earnings Season

by Urmimala Biswas

The Medical device companies' Q4 results are likely to reflect base business recovery on a year-over-year basis. Let's see how PRGO, COO and SGHT are poised ahead of their earnings releases.

Zacks Equity Research

Myriad Genetics (MYGN) Reports Loss in Q4, Gross Margin Improves

by Zacks Equity Research

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has drove Q4 sales despite a challenging business environment.

Zacks Equity Research

Here's How Much You'd Have If You Invested $1000 in Bio-Rad Laboratories a Decade Ago

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Zacks Equity Research

Integra's (IART) Q4 Earnings Top Estimates, Gross Margin Drops

by Zacks Equity Research

Integra (IART) records strong recovery in order demand in Q4 on broad-based strength in Neurosurgery and sales from the company's new CereLink ICP monitoring.

Zacks Equity Research

Insulet (PODD) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Insulet's (PODD) fourth-quarter 2021 revenues improved year over year on a strong performance of Omnipod, both in U.S. and international markets.

Zacks Equity Research

NuVasive (NUVA) Q4 Earnings Miss Estimates, Gross Margin Up

by Zacks Equity Research

Continued strong international performance and introduction of products drove NuVasive's (NUVA) revenues in the fourth quarter of 2021.